Expanded manufacturing Aurigene operates as a full-service CDMO with integrated API and formulation capabilities and has recently expanded facilities in Hyderabad and the United States, signaling capacity for larger-scale clinical and commercial production that sales teams can leverage to pitch end-to-end outsourcing solutions.

Global footprint With cGMP commercial manufacturing facilities in the UK, Mexico, USA, and India, Aurigene offers geographic diversification for clients seeking regional manufacturing and supply resilience, presenting an opportunity to target multinational pharma and biotech companies expanding global operations.

CRISPR and collaboration Recent integration with ERS Genomics' CRISPR/Cas9 patent portfolio enhances the translational potential for gene-editing and next-generation therapies, creating a compelling cross-sell for clients pursuing advanced modalities and requiring cutting-edge discovery support.

End-to-end capabilities Aurigene provides integrated services across medicinal chemistry, biology, preclinical, DMPK, development, and commercial manufacturing, enabling sales teams to position a single partner for molecule-to-market programs, reducing vendor fragmentation for clients.

Strategic partnerships Recent alliances with Kainomyx and Edity Therapeutics highlight Aurigene’s role as a collaborator for novel platforms and therapies, offering a gateway for co-development deals, technology licensing, and accelerated development engagements with innovative clients.